That musty smell could be more than just your old clothes, experts say.

Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; ...

This afternoon, we released financial results for the quarter and full year ended December 31, 2025, and recent corporate updates. The press release is available on the Investors section of our ...

Even a cursory read of the study will likely prompt questions, but let’s take the findings at face value based on what was ...

Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its fourth quarter and full year 2025 financial results and recent business activities. Participants ...

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, ...

Gross-to-net rebate reserve timing created quarterly net sales volatility, particularly in 2025 first and fourth quarters, ...

Net Sales Grew27% Year-Over-Year for the Fourth Quarter and 20% for the Full YearFourth Quarter GAAP Net Income and Earnings Per Share were $15 ...

Sarepta Therapeutics, Inc. ( SRPT) Q4 2025 Earnings Call February 25, 2026 4:30 PM EST ...

Water intake can boost metabolism and control appetite to help with weight loss. Replacing high-calorie drinks with water ...

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, To ...